Corcept's (NASDAQ:CORT) Q3 2026: beats on revenue

What happened

Corcept Therapeutics reported Q3 2026 revenue of $340.5 million, up 64% year on year and above analysts' estimates of $334.3 million. GAAP profit was $1.01 per share, beating estimates of $0.79, and the company reconfirmed full-year revenue guidance of $1.15 billion.

Confirmed

Global impact / market context

Faster revenue growth and a jump in operating margin to 33.7% from 4.9% mean Corcept keeps more profit from each sale. That could support spending on its Cushing's syndrome and ovarian cancer businesses without relying heavily on borrowed money.

Analyst inference

The results beat Wall Street's revenue and profit expectations while full-year guidance stayed close to consensus. Investors may weigh whether rapid uptake of Lifyorli in ovarian cancer and growing endocrinology demand can sustain this pace through the rest of 2026.

Analyst inference

What to watch

1. Corcept reconfirmed full-year 2026 revenue guidance of $1.15 billion at the midpoint, so future updates on whether actual sales track that figure will matter. Confirmed
2. Lifyorli launched April 1 and has reached more than 2,300 patients and over 1,700 prescribing physicians, so growth in these counts signals uptake. Confirmed
3. Watch whether operating margin stays near 33.7%, since holding it would show revenue growth is converting into profit rather than being consumed by higher costs. Analyst inference

Evidence

• stockstory.org